Goldman Sachs
KROS icon

Goldman Sachs’s Keros Therapeutics KROS Stock Holding History

Goldman Sachs’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.48M Sell
224,479
-366,038
-62% -$5.65M ﹤0.01% 4351
2025
Q4 		$12M Sell
590,517
-734,966
-55% -$12.9M ﹤0.01% 2911
2025
Q3 		$21M Buy
1,325,483
+441,923
+50% +$6.53M ﹤0.01% 2218
2025
Q2 		$11.8M Buy
883,560
+142,954
+19% +$1.93M ﹤0.01% 2612
2025
Q1 		$7.55M Buy
740,606
+205,022
+38% +$2.38M ﹤0.01% 2948
2024
Q4 		$8.48M Buy
535,584
+179,920
+51% +$9.35M ﹤0.01% 2957
2024
Q3 		$20.7M Sell
355,664
-165,783
-32% -$8.19M ﹤0.01% 2045
2024
Q2 		$23.8M Buy
521,447
+263,079
+102% +$14.1M ﹤0.01% 1744
2024
Q1 		$17.1M Buy
258,368
+53,269
+26% +$3.16M ﹤0.01% 1977
2023
Q4 		$8.15M Buy
205,099
+105,040
+105% +$3.29M ﹤0.01% 2718
2023
Q3 		$3.19M Buy
100,059
+26,152
+35% +$976K ﹤0.01% 3379
2023
Q2 		$2.97M Buy
73,907
+11,647
+19% +$511K ﹤0.01% 3563
2023
Q1 		$2.66M Sell
62,260
-83,562
-57% -$4.22M ﹤0.01% 3624
2022
Q4 		$7M Sell
145,822
-30,542
-17% -$1.43M ﹤0.01% 2885
2022
Q3 		$6.63M Buy
176,364
+28,513
+19% +$988K ﹤0.01% 2888
2022
Q2 		$4.09M Buy
147,851
+20,020
+16% +$878K ﹤0.01% 3344
2022
Q1 		$6.95M Buy
127,831
+8,533
+7% +$438K ﹤0.01% 3037
2021
Q4 		$6.98M Buy
119,298
+67,389
+130% +$3.36M ﹤0.01% 3102
2021
Q3 		$2.05M Buy
51,909
+29,439
+131% +$1.05M ﹤0.01% 4177
2021
Q2 		$954K Buy
22,470
+16,108
+253% +$873K ﹤0.01% 4795
2021
Q1 		$392K Sell
6,362
-117,553
-95% -$7.45M ﹤0.01% 5277
2020
Q4 		$8.74M Buy
123,915
+106,197
+599% +$6.69M ﹤0.01% 2572
2020
Q3 		$683K Buy
+17,718
New +$703K ﹤0.01% 4308

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Goldman Sachs's KROS Position: Q1 2026 in Review

Goldman Sachs reduced its Keros Therapeutics (KROS) stake by 62% in Q1 2026, selling an estimated $5.65M and leaving 224,479 shares worth $2.48M. The position accounts for ﹤0.01% of the portfolio, ranked #4351.

Goldman Sachs first reported a position in KROS in Q3 2020 and has held it in 23 quarters since. The position peaked at $23.8M in Q2 2024. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Goldman Sachs held 224,479 shares of Keros Therapeutics worth $2.48M as of Q1 2026.
  • Goldman Sachs sold 366,038 Keros Therapeutics shares in Q1 2026, an estimated $5.65M.
  • Keros Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4351 holding.
  • Goldman Sachs first reported a position in Keros Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Goldman Sachs's Keros Therapeutics position peaked at $23.8M in Q2 2024.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.